Skandinaviska Enskilda Banken Ab (Publ) Vir Biotechnology, Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$23.2 - $27.29 $5.29 Million - $6.22 Million	-228,000 Reduced 64.86%	123,500 $3.03 Million
Q1 2023 May 11, 2023	SELL	$22.26 - $30.85 $2.05 Million - $2.84 Million	-92,100 Reduced 20.76%	351,500 $8.18 Million
Q4 2022 Feb 08, 2023	BUY	$19.96 - $28.22 $8.85 Million - $12.5 Million	443,600 New	443,600 $11.2 Million
Q4 2020 Feb 11, 2021	SELL	$25.51 - $43.38 $5,612 - $9,543	-220 Closed	0 $0
Q1 2020 Jun 05, 2020	BUY	$12.04 - $60.2 $2,648 - $13,244	220 New	220 $8,000

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $991M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.